Compare · head to head
Day One Biopharmaceuticals vs Geron
Day One Biopharmaceuticals ranks higher overall — 360 rank 39 vs 22.
Day One Biopharmaceuticals leads on Quality (62 vs 55) and Safety (38 vs 21). The two are close on Value and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Small |
| ISIN | US23954D1090 | US3741631036 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 39 | 22 |
| Value | 47 | 51 |
| Quality | 62 | 55 |
| Growth | NR | 51 |
| Safety | 38 | 21 |
| Sentiment | 40 | 41 |
| Quality details | ||
| Profitability | 58 | 61 |
| Cash Truth | 65 | 50 |
Full analyses: Day One Biopharmaceuticals · Geron
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100